·|°T
Á`´Á¼Æ¡G²Ä1322´Á 2026¦~²Ä003´Á(115.01.19-115.01.23) ~~CAPA·|°T¤U¸ü~~
¬dÅçµn°O¬ÛÃö°T®§ ¡´ªñ ´Á °T ®§ ¡´¹Ãĸp©ó115¦~1¤ë27¤é(¬P´Á¤G)¤U¤È2®É30¤À¦b¥»¸p°ê®a¥Í§Þ¶é°ÏF´ÉF208·|ij«Ç¥l¶}ÃÄ«~¶´©Ê±Mªk»P°òª÷³W¹º°Q½×·|ij¡C¥ÑÃC¨q©ú¥D©e¡A·¨¤¯³Ç©eû¥Nªí¤½·|°Ñ¥[¡C ¡´¹Ãĸp©ó115¦~3¤ë17¤é(¤G)¤U¤È2®É¡A¦b¥»¸p°ê®a¥Í§Þ¬ã¨s¶é°Ï¿ì¤½«ÇF208·|ij«ÇÁ|¿ì115¦~«×²Ä¤@¦¸ÂåÀø¾¹§÷ªk³W¤ÎºÞ²z·¾³q°Q½×·|ij¡C
ÂåÀø¬Fµ¦»PÃÄ»ù¬ÛÃö°T®§ ¡´ ªñ ´Á °T ®§ ¡´¤½·|±N©ó115¦~01¤ë28¤é¤W¤È9ÂI-12ÂI¦b±iºaµo°òª÷·|801·|ij«ÇÁ|¿ì°·«O¤T¤Q©P¦~ÂåÀø¬ì§Þµû¦ô¥xÆWªº¾÷·|»P¬D¾Ô¡v½×¾Â¡AÁܽа·«O¸p±i¬êÙy°Æ¸pªø¤Î¨ä¥L¬ÛÃö¤Hû¨ÓºtÁ¿¤ÎPµü¡A¦³¦¬¶O2000¤¸Åwªï¤j®a¿ãÅD³ø¦W°Ñ¥[¡C
ÂåÀø°|©Òµo®i¬ÛÃö°T®§ ¡´ ¥» ¶g °T ®§ ¡´1¤ë23¤é(¤)¤U¤È13:30TPADAÁ|¿ì115¦~«×ESG®ö¼é¤UªºÂåÃĨó¦P¬ã°Q·|¡A¦aÂI¡G±iºaµo°òª÷·|°ê»Ú·|ij¤¤¤ß8F°ê»Ú·|ijÆU¡A¥Ñ¥j¯µ®Ñªø¥Nªí¤½·|°Ñ¥[¡C
·|°Èµo®i¬ÛÃö°T®§ ¡´ ¥» ¶g °T ®§ ¡´115¦~01¤ë21¤é(¤T)14:30¦b¤½·|·|ij«ÇÁ|¿ì²Ä24¦¸±`°È²zºÊ¨ÆÁp®u·|ij¡A¥Ñ²±Ä_¹Å²z¨Æªø¤Î¶À©ú¸qºÊ¨Æ¥l¶°¤H¦@¦P¥D«ù¡C ¡´ ªñ ´Á °T ®§ ¡´ÃÄ®`±ÏÀÙ°òª÷·|©ó115¦~01¤ë28(¤T)±ß¤W6:00¦b¥S§Ì¶º©±13¼Ó·|ijÆUÁ|¿ì°]¹Ïªk¤HÃÄ®`±ÏÀÙ°òª÷·|§À¤ú±ß®b¡AÁܽв±²z¨Æªø°Ñ¥[¡C
¡¯¤½·|¦¬¤å ½Ã¥ÍºÖ§Q³¡¤¤¥¡°·±d«OÀI¸p µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1140673070¸¹ ¨ç ¤½·|¦¬¤å115032¸¹(01¤ë) ¥D¦®¡G«¥Ó°·«O¦¬¸üÃÄ«~¡A³\¥iÃÒ«ù¦³ÃİӦ]¬G¤£¦A¨ÑÀ³¡A©Î¦³¤£¥i§Ü¤O¦]¯À¡APµLªk¨ÑÀ³®É¡AÀ³¨Ìªk¿ì²z¨Ã¶ñ¨ã¡uµu¯ÊÃÄ«~®w¦s¶q¤Î¨Ñ³fpµeªí¡v³q³ø¥»¸p¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|û¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1140059534¸¹ ¨ç ¤½·|¦¬¤å115037¸¹(01¤ë) ¥D¦®¡G¯÷³qª¾¥»«OÀI¥ÎÃÄ·s¼W¶µ¥Ø¡uBromhexineHydrochloride solution 2 mgmL¡v¡]°·«O¥N½XX000357148¡^¡A½ÐÂા©ÒÄÝ·|û¤Î¯S¬ùÂ卯ªA°È¾÷ºc¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1150670068¸¹ ¨ç ¤½·|¦¬¤å115040¸¹(01¤ë) µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1140673296¸¹ ¨ç ¤½·|¦¬¤å115041¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§tCEVIMELINE¦¨¤À¯S®íÃÄ«~EVOXAC(CEVIMELINE HCI CAPSULES 30MG)¦@¤@¶µ¥Ø¤ä¥I»ù®æ¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1150050468¸¹ ¨ç ¤½·|¦¬¤å115042¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§tcentella asiatica extract,Plectranthus amboinicus extract¦¨¤ÀÃÄ«~Fespixon cream¤ä¥I»ù¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1150050408¸¹ ¨ç ¤½·|¦¬¤å115043¸¹(01¤ë) ¥D¦®¡G¤½§i¼È¤©¤ä¥I§tbosutinib¦¨¤ÀÃÄ«~Bostini Film-Coated Tablets 100mg¡B400mg¤Î500mg¦@3¶µ¥Øµ¹¥I³W©w¡Aº[×q§tdasatinibÃÄ«~¡]¦pSprycel¡^¡B§tnilotinibÃÄ«~(¦pTasigna)¤Î§tponatinibÃÄ«~¡]¦pIclusig¡^¤§µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B ªþ¥ó2 µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1140059120¸¹ ¨ç ¤½·|¦¬¤å115044¸¹(01¤ë) ¥D¦®¡G¤½§i¼È¤©¤ä¥I§trepotrectinib¦¨¤ÀÃÄ«~AUGTYRO Capsules 40 mg¤Î¨äÃÄ«~µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B ªþ¥ó2 µo¤å¤é´Á/¤å¸¹¡G115.01.19/ °·«O¼f¦r²Ä1150670076¸¹ ¨ç ¤½·|¦¬¤å115045¸¹(01¤ë) ¥D¦®¡G¤½§i×q§tbotulinum toxin type A¦¨¤ÀÃÄ«~(¦pBotox)¤§ÃÄ«~µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150050262¸¹ ¨ç ¤½·|¦¬¤å115050¸¹(01¤ë) ¥D¦®¡G¯÷³qª¾¥»«OÀI¥ÎÃÄ·s¼W¶µ¥Ø¡uProstin E2(Dinoprostone) 3mg vaginal tablets¡v¡]°·«O¥N½XX000360500¡^¡A½ÐÂા©ÒÄÝ·|û¤Î¯S¬ùÂ卯ªA°È¾÷ºc¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150050460¸¹ ¨ç ¤½·|¦¬¤å115053¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§ttrifluridinetipiracil¦¨¤ÀÃÄ«~LONSURF Film-Coated Tablets 15mg¤Î20mg¦@2¶µ¥Ø¤ä¥I»ù®æ¤Î×q¨äµ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B ªþ¥ó2 µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150050397¸¹ ¨ç ¤½·|¦¬¤å115054¸¹(01¤ë) ¥D¦®¡G¤½§i×q§tinebilizumab¦¨¤ÀÃÄ«~¤§ÃÄ«~µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150050507¸¹ ¨ç ¤½·|¦¬¤å115055¸¹(01¤ë) ¥D¦®¡G¤½§i×q§tPanitumumab¦¨¤ÀÃÄ«~¤§ÃÄ«~µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150050491¸¹ ¨ç ¤½·|¦¬¤å115056¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§tcetuximab¦¨¤ÀÃÄ«~Erbitux 5mgml Solution for infusion¤ä¥I»ù®æ¤Î×q¨äµ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B °Æ¥ó1¡B ªþ¥ó2 µo¤å¤é´Á/¤å¸¹¡G115.01.20/ °·«O¼f¦r²Ä1150670140¸¹ ¨ç ¤½·|¦¬¤å115057¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§tnivolumab¦¨¤ÀÃÄ«~Opdivo Injection 10mgmL¤Î12mgmL¤§°·«O¤ä¥I»ù®æ¤Î×q¨äÃÄ«~µ¹¥I³W©w¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B ªþ¥ó2 µo¤å¤é´Á/¤å¸¹¡G115.01.22/ °·«O¼f¦r²Ä1150050172¸¹ ¨ç ¤½·|¦¬¤å115061¸¹(01¤ë) ¥D¦®¡G¤½§i·s¼W§tneomycin ¦¨¤À¤@¯ë¿õ¾¯½¦Ån¾¯Neomycin Capsules 250mg¦@1¶µ¥ØÃÄ«~¬°¤£¥i´À¥N¯S®íÃÄ«~¤Î²§°Ê¨ä¤ä¥I»ù®æ¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.22/ °·«O¼f¦r²Ä1150050330¸¹ ¨ç ¤½·|¦¬¤å115062¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§trabies immune globulin¦¨¤Àª`®g¾¯HyperRAB 300IU/ml,1mL¤§¤£¥i´À¥N¯S®íÃÄ«~¦@1¶µ¥Ø¤§¤ä¥I»ù®æ¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.23/ °·«O¼f¦r²Ä1150050398¸¹ ¨ç ¤½·|¦¬¤å115066¸¹(01¤ë) ¥D¦®¡G¤½§i²§°Ê§terlotinib¦¨¤ÀÃÄ«~Tarceva Film-coated tablets 150mg¤Î100mg¦@2¶µ¥Ø¤ä¥I»ù®æ¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.23/ °·«O¼f¦r²Ä1150670199¸¹ ¨ç ¤½·|¦¬¤å115070¸¹(01¤ë) ¥D¦®¡G¦³Ãö115¦~2¤ë¥÷¥þ¥Á°·±d«OÀIÃÄ«~»ù®æ¤§²§°Ê±¡§Î¡A¸Ô¦pÃÄ«~»ù®æ©ú²Óªí¡]p88¶µ¡^¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|û©Î¯S¬ùÂåÀø°|©Ò¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1
½Ã¥ÍºÖ§Q³¡ µo¤å¤é´Á/¤å¸¹¡G115.01.21/ ½Ã±Â¹¦r²Ä1141403896¸¹ ¨ç ¤½·|¦¬¤å115058¸¹(01¤ë) ¥D¦®¡G¡u°·±d¹«~¤§G¸z¥\¯à§ïµ½µû¦ô¤èªk¡v¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê115¦~1¤ë20¤é¥H½Ã±Â¹¦r²Ä1141303438¸¹¤½§i×¥¿µo¥¬¡A¨Ã×¥¿¬°¡u°·±d¹«~¤§G¸z¥\¯à§ïµ½«O°·¥\®Äµû¦ô¤èªk¡v¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B µo¤å¤é´Á/¤å¸¹¡G115.01.23/ ½Ã±Â¹¦r²Ä1159000222¸¹ ¨ç ¤½·|¦¬¤å115067¸¹(01¤ë) ¥D¦®¡G¨çÂà¹A·~³¡©ó115¦~1¤ë2¤é¹A±Â¨¾¦r²Ä1141862390¸¹¤½§iq©w¡uÃħ½À³©w´Á¥Ó³ø¨ÌÃ~Âå®v¡]¦õ¡^¶}¥ßÁÊÃÄÃÒ©ú©Ò¨ÑÀ³¤H¥ÎÃÄ«~¸ê®Æ¥Ó³ø¤è¦¡¡v¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B µo¤å¤é´Á/¤å¸¹¡G115.01.23/ ½Ã±Â¹¦r²Ä1159000223¸¹ ¨ç ¤½·|¦¬¤å115068¸¹(01¤ë) ¥D¦®¡G¨çÂà¹A·~³¡©ó115¦~1¤ë2¤é¹A±Â¨¾¦r²Ä1141862179¸¹¥Oq©wµo¥¬¡uÃİÓÀ³©w´Á¥Ó³ø°Êª««OÅ@ÃÄ«~³c½æ¸ê®Æ¥Ó³ø§@·~nÂI¡v¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B ªþ¥ó2
½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p µo¤å¤é´Á/¤å¸¹¡G115.01.19/ FDAÃĦr²Ä1150700489¸¹ ¨ç ¤½·|¦¬¤å115038¸¹(01¤ë) ¥D¦®¡G¦³Ãö¶Q¤½¥q¥Ó½Ð½Õ¾ã¡u©T¸¡¶¶½¤¦ç¿õ5²@§J¡AGooficeFilm-Coated Tablets 5 mg¡]½Ã³¡ÃÄ»s¦r²Ä062079¸¹¡^¡vÃÄ«~¦w¥þ©Ê©w´Á³ø§i¤§¸ê®Æ»`¶°ºI¤î¤é (DLP) ¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ FDAÃĦr²Ä1151400134¸¹ ¨ç ¤½·|¦¬¤å115047¸¹(01¤ë) ¥D¦®¡GÀ˰e¡uÃÄ«~ÂåÀø¾¹§÷¹«~¤ÆùÛ«~¤W¥««á«~½èºÞ²z¨t²Î¡v¤§¡uE¬F©²µn¤J¾Þ§@¤â¥U¡v1¥÷¡A½Ð´f¤©Âા©ÒÄÝ·|û°t¦X¿ì²z¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.19/ FDAÃĦr²Ä1150700958¸¹ ¨ç ¤½·|¦¬¤å115048¸¹(01¤ë) ¥D¦®¡G¦³Ãö¶Q¤½¥q¥Ó½Ð½Õ¾ã¡u®¦¥²´_á´¹ª`®g¾¯¡AEmblaveo 1.5g0.5g powder for concentrate for solution forinfusion¡vÃÄ«~¦w¥þ©Ê©w´Á³ø§i¤§¸ê®Æ»`¶°ºI¤î¤é (DLP) ¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ FDAÃĦr²Ä1150700959¸¹ ¨ç ¤½·|¦¬¤å115049¸¹(01¤ë) ¥D¦®¡G¦³Ãö¶Q¤½¥q¥Ó½Ð½Õ¾ã¡u¤Í³Ó°±¹w¶ñ¥Rª`®gµ§150²@§J¡AHYMPAVZI 150 mg solution for injection inprefilled pen¡vÃÄ«~¦w¥þ©Ê©w´Á³ø§i¤§¸ê®Æ»`¶°ºI¤î¤é (DLP) ¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.20/ FDAÃĦr²Ä1141404345¸¹ ¨ç ¤½·|¦¬¤å115051¸¹(01¤ë) ¥D¦®¡G´f½Ð¶Q·|Âા©ÒÄÝ·|û¡A¡uÃÄ«~¬dÅçµn°O¼f¬dº[½u¤W¥Ó½Ð§@·~¥»O(ExPRESS)¡v¶}©ñ¡u¦A¥ÍÂåÀø»s¾¯¡v¡B¡ueCTDBase-line¡vµ¥2¶µ¥Ó½Ð®×¥ó½u¤W¥Ó¿ì¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.20/ FDA¾¹¦r²Ä1151600504¸¹ ¨ç ¤½·|¦¬¤å115052¸¹(01¤ë) ¥D¦®¡G´£¿ô¦³Ãö¥ø·~¸gÀçªÌ¥H¡u§K¶O¸Õ¥Î¡v©Î¡uÀu´f»ù¡vµ¥»¤¦]§l¤Þ®ø¶OªÌ¡A¨Ã¹w³]´Áº¡«á¦Û°Êq¡þÄò¬ù¦©´Úµ¥¦æ¾P¼Ò¦¡l¥Í¤§®ø¶Oª§Ä³±¡¨Æ¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|û¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.21/ FDAÃĦr²Ä1150001590¸¹ ¨ç ¤½·|¦¬¤å115059¸¹(01¤ë) ¥D¦®¡G¦³Ãö¶Q¤½¥q¥D°Ê¦^¦¬ÃÄ«~¡u«ä¦³±o«ùÄò©ÊÃĮĽ¦Ån44²@§J¡]½Ã³¡ÃÄ»s¦r²Ä060153¸¹¡^¡v¡]§å¸¹M082012¡^¤@®×¡A½Ð¨Ì»¡©ú¬q¿ì²z¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.21/ FDA«~¦r²Ä1151100402¸¹ ¨ç ¤½·|¦¬¤å115060¸¹(01¤ë) ¥D¦®¡G¦³Ãö¬ü°êFDAµo¥¬¬ü°êì®ÆÃļtWarning Letter¤A®×¡A½ÐÂા©ÒÄÝ·|ûª¾·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.22/ FDAÃĦr²Ä1151400314¸¹ ¨ç ¤½·|¦¬¤å115063¸¹(01¤ë) ¥D¦®¡G¦³Ãö¤½§i¡uICH E9¡GÁ{§É¸ÕÅç²Îp«ü¾Éì«h¦³Ãö¤½§i¡uICH E9¡GÁ{§É¸ÕÅç²Îp«ü¾Éì«h(STATISTICAL PRINCIPLES FOR CLINICAL TRIALS)¡v¤@®×¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.22/ FDAÃĦr²Ä1151400335¸¹ ¨ç ¤½·|¦¬¤å115064¸¹(01¤ë) ¥D¦®¡G¦³Ãö¤½§i¡uICH E19¡G¦b¯S©w¤W¥««á©Î¤W¥««e±ß´ÁÁ{§É¸ÕÅ礤±Ä¥Î¿ï¾Ü©Ê¦w¥þ©Ê¸ê®Æ»`¶°¤èªk(A SELECTIVEAPPROACH TO SAFETY DATA COLLECTION IN SPECIFICLATE-STAGE PRE-APPROVAL OR POST-APPROVAL CLINICALTRIALS)¡v¤@®×¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.65/ FDA«~¦r²Ä1151100429¸¹ ¨ç ¤½·|¦¬¤å115065¸¹(01¤ë) ¥D¦®¡G¦³Ãö¥»¸p¤µ(115)¦~«×°ê¤ºÂåÀø¾¹§÷»s³y¼t¥DÃD¦¡Àˬdpµe¤§°ê¤ºÂåÀø¾¹§÷»s³y¼t¤£©w´ÁÀˬd¤u§@¡A©e¥Ñ°]¹Îªk¤H¶ì½¦¤u·~§Þ³Nµo®i¤¤¤ß°õ¦æ¡A½ÐÂા©ÒÄÝ·|û¡C¡° ¤½¨ç¤U¸ü¡B µo¤å¤é´Á/¤å¸¹¡G115.01.23/ FDA¬ã¦r²Ä1151900129¸¹ ¨ç ¤½·|¦¬¤å115069¸¹(01¤ë) ¥D¦®¡G¦³Ãö¤¤µØÃĨå²Ä¤Qª©¤£¦A¦¬¸ü³q«h¤Î«~¥Ø²M³æ¯ó®×¡A½Ð´f¥Ü¨ô¨£¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1
»O¥_¥«¬F©²½Ã¥Í§½ µo¤å¤é´Á/¤å¸¹¡G115.01.19/ ¥_¥«½Ã¹ÃĦr²Ä1153063992¸¹ ¨ç ¤½·|¦¬¤å115033¸¹(01¤ë) ¥D¦®¡G¦³Ãö»OÆWªü´µ¯S±¶§Q±dªÑ¥÷¦³¤½¥q«ù¦³¡u¥i·À³ÝÄa¯B§l¤J²G1¤½µ·2¤½¼¼¡v¡]½Ã¸pÃÄ¿é¦r²Ä022049¸¹¡^ÃÄ«~³\¥iÃÒ·~¸g½Ã¥ÍºÖ§Q³¡¤½§iµù¾P¤@®×¡A½Ð¶Q·|Âા©ÒÄÝ·|û¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1¡B µo¤å¤é´Á/¤å¸¹¡G115.01.19/ ¥_¥«½Ã¹ÃĦr²Ä1153064021¸¹ ¨ç ¤½·|¦¬¤å115034¸¹(01¤ë) ¥D¦®¡G¦³Ãö¬ü°Ó´f¤óÃļt(¨È¬w)ªÑ¥÷¦³¤½¥q¥xÆW¤À¤½¥q«ù¦³¡u½F®¦´µ ª`®g¾¯¡v(½Ã³¡µß¬Ì¿é¦r²Ä001165¸¹)ÃÄ«~³\¥iÃÒ·~¸g½Ã¥ÍºÖ§Q³¡¤½§iµù¾P¤@®×¡A½Ð¶Q·|Âા©ÒÄÝ·|û¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1 µo¤å¤é´Á/¤å¸¹¡G115.01.19/ ¥_¥«½Ã¹ÃĦr²Ä1153064024¸¹ ¨ç ¤½·|¦¬¤å115035¸¹(01¤ë) ¥D¦®¡G¦³Ãö¬ü°Ó´f¤óÃļt(¨È¬w)ªÑ¥÷¦³¤½¥q¥xÆW¤À¤½¥q«ù¦³¡u¦ã³tµªª`®g²G¾¯¡v(½Ã³¡µß¬Ì¿é¦r²Ä001157¸¹)ÃÄ«~³\¥iÃÒ·~¸g½Ã¥ÍºÖ§Q³¡¤½§iµù¾P¤@®×¡A½Ð¶Q·|Âા©ÒÄÝ·|û¡A½Ð¬d·Ó¡C¡° ¤½¨ç¤U¸ü¡B ªþ¥ó1
¤¤µØ¥Á°ê¥þ°ê°Ó·~Á`·| µo¤å¤é´Á/¤å¸¹¡G115.01.19/ ¥þ°Ó³Ð¦r²Ä1150000130¸¹ ¨ç ¤½·|¦¬¤å115046¸¹(01¤ë) ¥D¦®¡G°ÓÁ`Á|¿ì²Ä¤K©¡«~µPª÷²í¼ú¼x¿ï©Û¶Ò¡A·q½Ð¬d·Ó¨ÃÂા¶Q·|©ÒÄÝ·|û¡C¡° ¤½¨ç¤U¸ü¡B
|